Template Clinical Trial Agreement 2015 – the NetherlandsTrial Agreement • November 12th, 2020
This template clinical trial agreement is created in joint cooperation between the vereniging Samenwerkende Topklinische opleidingsZiekenhuizen (STZ), Nefarma, Stichting Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI/AvL) and ACRON, to facilitate conducting clinical trials in The Netherlands. The clauses on termination and publication meet the Directive on the Assessment of the Clinical Trial Agreement of the CCMO.
ContractTrial Agreement • July 7th, 2023
ZMLUVA O KLINICKOM SKÚŠANÍ CLINICAL TRIAL AGREEMENT uzatvorená podľa § 269 ods. 2 a nasl. zákona č. 513/1991 Zb. Obchodný zákonník v platnom znení (ďalej len „obchodný zákonník”) (ďalej len „Zmluva“) concluded pursuant to Section 269 (2) of Act no.513/1991 of Coll., the Commercial Code, as amended (hereinafter referred to as the “Commercial Code”) (hereinafter referred to as the “Agreement”) Medzi Between Karyopharm Therapeutics, Inc.so sídlom: 85 Wells Avenue, Newton, MA 02459 USAIČO.: 4637137DIČ: 26-3931704zapísaná v obchodnom registri vedenom štátom Delaware,konajúca prostredníctvom: Stuarta Poultona, viceprezidenta a riaditeľa pre rozvoj (ďalej len “Zadávateľ”) Karyopharm Therapeutics, Inc.Registered office: 85 Wells Avenue, Newton, MA 02459 USAID No.: 4637137VAT No.: 26-3931704Registered with the Commercial Register kept by the State of Delaware. Represented by: Executive Vice President, Chief Development Officer, Stuart Poulton (hereinafter referred to as the “Sponsor”) Karyophar
ContractTrial Agreement • May 5th, 2020
SMLOUVA O PROVEDENÍ KLINICKÉHO HODNOCENÍCLINICAL TRIAL AGREEMENT Klinické hodnocení: CA209-602 Clinical Trial: CA209-602 „Otevřená, randomizovaná studie fáze 3 hodnotícíkombinace nivolumabu, elotuzumabu, pomalidomidu a dexametazonu u relabovaného a refrakterníhomnohočetného myelomu“ “An Open-Label, Randomized Phase 3 Trial ofCombinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed andRefractory Multiple Myeloma” dále jen „smlouva“. hereinafter “Agreement”. doc. MUDr. Luděk Pour, Ph.D. doc. MUDr. Luděk Pour, Ph.D. xxx xxx xxx xxx xxx xxx Datum narození: xxx Date of Birth: xxx dále jen „zkoušející“ hereinafter “Investigator” a and Fakultní nemocnice Brno Fakultní nemocnice Brno jednající MUDr. Romanem Krausem, MBA, ředitelem Represented by Roman Kraus, MD, MBA, director Jihlavská 20 Jihlavská 20 625 00 Brno 625 00 Brno Česká republika Czech Republic IČO: 65269705 Identification No.: 65269705 DIČ: CZ65269705 Tax Identification No.: CZ65269705 dále jen „zhotovitel“
ContractTrial Agreement • February 19th, 2018
Clinical Trial Agreement Smlouva o klinickém hodnocení The Clinical Trial Agreement (“Agreement”) is made by and between: Tato smlouva o klinickém hodnocení(“Smlouva”) je uzavírána mezi následujícími stranami: • Fakultní nemocnice Brno, having a place of business at Jihlavská 20, 625 00 Brno, Czech Republic, Identification number: 65269705, Tax identification number: CZ65269705, Acting by: MUDr. RomanKraus, MBA - Director “Institution”), and • Fakultní nemocnice Brno, se sídlem Jihlavská 20, 625 00 Brno, Česká republika, IČ: 65269705, DIČ: CZ65269705, jednající: MUDr. Roman Kraus, MBA - ředitel (“Zdravotnické zařízení”), a • , born on, having a address at (the “Investigator”),and • , nar., s adresou (“Zkoušející”), a • Quintiles Czech Republic, s.r.o., having a place of business at Praha 5, Jinonice, Radlická 714/113a, zip code 158 00 Prague, Czech Republic, Identification number: 247 68 651, Tax identification number: CZ247 68 651, represented by Mr. AlasdairMacDonald (“Quintiles”), a
CLINICAL TRIAL AGREEMENT – NON COMMERCIAL NON-RETROSPECTIVE STUDY – MONOCENTRIC ZOL SPONSOREDTrial Agreement • January 14th, 2021
Ziekenhuis Oost-Limburg, with registered office at 3600 Genk, Schiepse Bos 6, and registered with the Legal Entities Register under the business registration number 0256.543.917 hereby represented by its chairman, Mr. Tom Arts, its managing director, Mr. Erwin Bormans and its medical director, Dr. Griet Vander Velpen
CLINICAL TRIAL AGREEMENT FOR THE DRUG(S) “__________” BETWEENTrial Agreement • April 15th, 2024
Istituto clinico Humanitas – Humanitas Mirasole S.p.A. shareholder company (hereinafter the “Entity”), headquartered in Rozzano (Milan) Zip code 20089, Via Alessandro Manzoni 56, Tax Code 10125410158, VAT no. 10982360967 , through its Legal Representative Mr. Luciano Ravera , in his capacity as managing director with the powers to enter into this agreement
CLINICAL TRIAL AGREEMENT FOR PROTOCOL GS-US-419-3895Trial Agreement • August 17th, 2018
DIČ DPH: SK 202 17 00 549, ktorej menom koná štatutárny kolektívny orgán: Rada riaditeľov, Názov banky a adresa: Všeobecná úverová banka a.s., Mlynské Nivy 1, 829 00, Bratislava, Slovenská republika, Bankové spojenie:......, IBAN: ,
ZMLUVA O KLINICKOM SKÚŠANÍ CLINICAL TRIAL AGREEMENTTrial Agreement • November 14th, 2023
concluded pursuant to Section 269 (2) of Act no. 513/1991 of Coll., the Commercial Code, as amended (hereinafter referred to as the “Commercial Code”) (hereinafter referred to as the “Agreement”)
ContractTrial Agreement • March 23rd, 2024
Clinical Trial Agreement The Clinical Trial Agreement (“Agreement”) is made by and between:• Fakultní nemocnice v Motole, having a place of business at V Úvalu 84150 06 Prague 5, Czech Republic, Identification number: 00064203, Tax identification number:CZ00064203, representedbased on a mandate dated 29 November 2016 (the “Institution”), and • Quintiles Czech Republic, s.r.o., having a place of business at Praha 5, Jinonice, Radlická 714/113a, zip code 158 00 Prague, Czech Republic, Identification number: 247 68 651, Tax identification number: CZ24768651, represented by Mr. Alasdair MacDonald (“Quintiles”), and • Archigen Biotech Limited, having a place of business at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambrigde CB2 0AA, United Kingdom, Identification number: 08997356, Tax identification number:GB193046016], represented by (“Sponsor”) Each a “Party” and together the “Parties”. Smlouva o klinickém hodnocení Tato smlouva o klinickém hodnocení (“Smlouva”) je uzavírána me
RECITALSTrial Agreement • August 13th, 2001 • Northwest Biotherapeutics Inc • Textile mill products • California
SMLOUVA O PROVEDENÍ KLINICKÉHO HODNOCENÍ CLINICAL TRIAL AGREEMENTTrial Agreement • April 16th, 2021
„Studie hodnotící léčbu nivolumabem v kombinaci s trametinibem s nebo bez ipilimumabu u pacientů s dříve léčeným metastatickým kolorektálním karcinomem.“ “A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers”
ContractTrial Agreement • September 10th, 2024
CLINICAL TRIAL AGREEMENT SMLOUVA O KLINICKÉM HODNOCENÍ Protocol # 217013 Protokol číslo 217013 This Clinical Trial Agreement (“Agreement”) dated as of the date of last signature and effective as of the date of publication of the Redacted Agreement into the Contracts Registry (hereinafter defined) (“Effective Date”) between Tato smlouva o klinickém hodnocení (dále jen„smlouva“) ze dne připojení posledního podpisu s účinností k datu uveřejnění upravené smlouvy (definované níže) v registru smluv (definovaném níže) („datum účinnosti“) se uzavírá mezi Syneos Health UK Limited with principal offices located in the United Kingdom at Farnborough Business Park, 1 Pinehurst Road, Farnborough, Hampshire, GU14 7BF, United Kingdom, including its affiliates, subsidiaries, and specifically its parent company Syneos Health, LLC (“CRO”) společností Syneos Health UK Limited se sídlem ve Velké Británii na adrese Farnborough Business Park, 1 Pinehurst Road, Farnborough, Hampshire, GU14 7BF
ZMLUVA 0 KLINICKOM SKÚŠANÍ CLINICAL TRIAL AGREEMENT uzatvorená podľa § 269 ods. 2 a nasl. zákona č. 513/1991 Zb. Obchodný zákonník v platnom znení (ďalej len „Obchodný zákonník”) (ďalej len„Zmluva") concluded pursuant to Section 269 (2) of Act no....Trial Agreement • February 14th, 2024
VZHĽADOM K TOMU, ŽE Pfizer Inc. je zadávateľom klinického skúšania („Zadávateľ alebo „Pfizer“) so skúšaným liekom ARV-471 (PF-07850327) (ďalej len "Skúšaný liek") s názvom " A PHASE 3, RANDOMIZED,OPEN-LABEL , MULTICENTER STUDY OF ARV-471 (PF-07850327) PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTOR POSITIVE, HER2-NEGAT1VE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI-CANCER TREATMENT FOR ADVANCED DISEASE (VERITAC-3) ” (ďalej len"Klinické skúšanie"), ktoré je bližšie popísané vprotokole č. C4891002, ktorý bude Zmluvným partnerom odovzdaný Zadávateľom a ktorý môže byť Zadávateľom jednostranne doplňovaný (ďalej len"Protokol"). WHEREAS, Pfizer Inc. is the Sponsor of the clinical trial (“Sponsor” or “Pfizer") involving the study drug ARV-471 (PF-07850327) (hereinafter called the “Investigational medicinal product”) named “A PHASE 3, RANDOMIZED,OPEN-LABEL MULTICENTER STUDY OF ARV-471 (PF-07850327) PLUS PALBOCICLIB VER
CLINICAL TRIAL AGREEMENTTrial Agreement • April 4th, 2021 • Uttar Pradesh
Sanjay Gandhi Post Graduate Institute of Medical Sciences, Rae Bareli Road, Lucknow is a super specialty hospital, established by Government of Uttar Pradesh, as a center of excellence for providing medical care, education and research of high order and is chartered to function as a university under Sanjay Gandhi Post Graduate Institute of Medical SciencesAct, 1983. [Hereinafter referred to as “Act”]
Clinical Trial Agreement Smlouva o klinickém hodnoceníTrial Agreement • July 22nd, 2020
• Fakultní nemocnice Plzeň, having a place of business at Edvarda Beneše 1128/13, 305 99 Plzeň, Czech Republic, Identification number: 00669806, Tax identification number: CZ00669806, represented by MUDr. Václav Šimánek Ph.D., Director (the “Institution”), and
ContractTrial Agreement • December 27th, 2019
Clinical Trial Agreement Smlouva o KLINICKÉM HODNOCENÍ The Clinical Trial Agreement (“Agreement”) is made by and between: Tato smlouva o klinickém hodnocení („Smlouva“) je uzavírána mezi následujícími stranami: • Thomayerova nemocnice, located at Vídeňská 800, 140 59 Praha 4 – Krč, Czech Republic, Identification number: 00064190, Tax identification number: CZ00064190, state contributory organization established by the Ministry of Health of the Czech Republic, full text of foundation deed No. MZDR 17268-IV/2012, registered in Companies Registry by Municipal Court in Prague, Section PR, inlet 1043 represented by doc. MUDr. Zdeněk Beneš CSc., Director (the “Institution”); and • Thomayerova nemocnice, se sídlem Vídeňská 800 140 59 Praha 4 – Krč, Česká republika, Identifikační číslo: 000 64 190, Daňové identifikační číslo: CZ00064190, státní příspěvková organizace zřízená Ministerstvem zdravotnictví ČR, úplné znění zřizovací listiny č.j. MZDR 17268-IV/2012, zapsaná v obchodním rejstříku u M
ContractTrial Agreement • September 20th, 2016
CLINICAL TRIAL AGREEMENT SMLOUVA O KLINICKÉM HODNOCENÍ (CRO-Janssen-Institution/PrincipalInvestigator) (CRO, Janssen a zdravotnické zařízení /hlavní zkoušející) This Clinical Trial Agreement (the“Agreement”) is Tato Smlouva o klinickém hodnocení (dálejen „Smlouva“) je by and between uzavírána mezi společností Quintiles Czech Republic, s.r.o. (“CRO”), a company organized and existng under the laws of the Czech Republic with its principal offices located in Radlická 714, 158 00 Praha 5, Czech Republic, represented by Alasdair MacDonald And Janssen- Cilag International NV (“Janssen”), a Belgian corporation, with registered offices at Turnhoutseweg 30. B-2340, Beerse, Belgium Quintiles Czech Republic, s.r.o., (dále „CRO”), společností založenou a fungující podle zákonů České republiky, se sídlem společnosti Radlická 714, 158 00 Praha 5, Česká republika, zastoupenou Alasdairem MacDonaldem, jednatelem, a společností Janssen- Cilag International NV (dále jen „společnost Janssen”), společností
ContractTrial Agreement • July 4th, 2018
Clinical Trial Agreement SMLOUVA O KLINICKÉM HODNOCENÍ The Clinical Trial Agreement (“Agreement”) is made by and between: Tato smlouva o klinickém hodnocení (“Smlouva”) je uzavírána mezi následujícími stranami: • Všeobecná fakultní nemocnice v Praze, having a place of business at U Nemocnice 499/2, 128 08 Praha 2, Czech Republic, Identification number: 00064165, Tax identification number: CZ00064165, represented by Mgr. Dana Jurásková, Ph.D., MBA, Director (the “Institution”), and • Všeobecná fakultní nemocnice v Praze, se sídlem U Nemocnice 499/2, 128 08 Praha 2, Česká republika, Identifikační číslo: 00064165, Daňové identifikační číslo: CZ00064165, zastoupená Mgr. Danou Juráskovou, Ph.D., MBA, ředitelkou (“Zdravotnické zařízení”), a • , having an address at, date of birth: (the “Investigator”),a • , s adresou, datum narození: (“Zkoušející”), a • IQVIA RDS Czech Republic s.r.o., having a place of business at Pernerova 691/42, 186 00 Praha 8 - Karlín, Czech Republic, Identification num
INSTITUTION CLINICAL TRIAL AGREEMENT SMLOUVA SE ZDRAVOTNICKÝM ZAŘÍZENÍM O PROVEDENÍ KLINICKÉHO HODNOCENÍTrial Agreement • February 28th, 2019
This Institution Clinical Trial Agreement (“Agreement”) effective as of the last date of signature (“Effective Date”) by and among: Covance Inc, a corporation of the State of Delaware, having its principal place of business 206 Carnegie Center, Princeton, New Jersey 08450, USA, and its affiliates (hereinafter referred to as “Covance”); and Oblastní nemocnice Kolín, a.s., nemocnice Středočeského kraje, Žižkova 146, 280 02 Kolín, Česká republika represented by Petre Chudomel, MD, MBA, chairmen of the Board and Igor Karen, MD, vice-chairmen of the Board, (hereinafter referred to as “Institution”) Whereas, Covance and Institution are hereinafter referred to individually as “Party” and collectively as “Parties”; Whereas, Covance is acting in its capacity as a contract research organization as defined in ICH-GCP 1.20 as an independent contractor of OMEICOS Therapeutics GmbH having its principal offices at Robert-Rössle-Straße 10 (Building 79), 13125 Berlin, Germany (“Sponsor”) to a
AMENDMENT NO. 1 TO CLINICAL TRIAL AGREEMENT BETWEEN ECOG-ACRIN CANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC.Trial Agreement • January 4th, 2016 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 1 to Clinical Trial Agreement (the “Amendment” or “Amendment 1”) is entered into as of January 30, 2015 (the “Effective Date”) by and between ECOG-ACRIN Cancer Research Group, successor entity to the Eastern Cooperative Oncology Group, on behalf of itself and its member hospitals, institutions and physicians (the “Group,” “ECOG” or “ECOG-ACRIN”), and Syndax Pharmaceuticals, Inc. (“Company” or “Syndax”).
ContractTrial Agreement • February 15th, 2018
CLINICAL TRIAL AGREEMENT SMLOUVA O KLINICKÉM HODNOCENÍ The Clinical Trial Agreement (together with all Attachments and Exhibits thereto, the “Agreement”) is made by and between: Smlouvu o klinickém hodnocení (společně se všemi Přílohami a Dodatky, dále jen „Smlouva”) uzavírají: Fakultní nemocnice Královské Vinohrady, having a place of business at Šrobárova 1150/50, 100 34 Praha 10, Czech Republic,Identification Number: 000 64 173, TaxIdentification Number: CZ 000 64 173, represented by doc. MUDr. Robert Grill, Ph.D., MHA, Director, reference symbol: KH 32/2017, internal cost center no. 43033 (the “Institution” or the “Site”), and Fakultní nemocnice Královské Vinohrady, se sídlem Šrobárova 1150/50, 100 34 Praha 10,Česká republika, IČO: 000 64 173, DIČ: CZ 000 64 173, zastoupená doc. MUDr. Robertem Grillem, Ph.D., MHA, ředitelem, číslo jednací: KH 32/2017, interní nákladové středisko: 43033 („Zdravotnické zařízení“ nebo „Centrum klinického hodnocení“), a Quintiles Czech Republic, s.r
ContractTrial Agreement • November 27th, 2019
Clinical Trial Agreement Smlouva o klinickém hodnocení The Clinical Trial Agreement (“Agreement”) is made by and between: • Nemocnice Na Bulovce, having a place of business at Budínova 67/2, 180 81 Praha 8, Czech Republic, Identification number: 00064211, Tax identification number: CZ00064211, represented by Tato smlouva o klinickém hodnocení (dále jen„Smlouva“) je uzavírána mezi následujícími stranami:• Nemocnice Na Bulovce, se sídlem Budínova 67/2, 180 81 Praha 8, Česká republika, IČO: 00064211, DIČ: CZ00064211, zastoupená(dále jen „Zdravotnické zařízení“); a (the “Institution”); and • IQVIA RDS Czech Republic s.r.o., having a place of business at Pernerova 691/42, 186 00 Praha 8 - Karlín, Czech Republic, Identification number: 247 68 651, Tax identification number: CZ24768651, represented by Ing. Martin Šlégl, Managing Director (“IQVIA”); and • IQVIA RDS Czech Republic s.r.o., se sídlem Pernerova 691/42, 186 00 Praha 8 - Karlín, Česká republika, IČO: 247 68 651, DIČ: CZ24768651,
CLINICAL TRIAL AGREEMENT FOR PROTOCOL GS-US-417-0303 SMLOUVA O KLINICKÉM HODNOCENÍ V RÁMCI PROTOKOLU GS-US-417-0303Trial Agreement • January 18th, 2018
This Clinical Trial Agreement (“Agreement”) by and between: Tato smlouva o klinickém hodnocení (dále jen „Smlouva“) se uzavíra mezi:
CLINICAL TRIAL AGREEMENT WITH INSTITUTION SMLOUVA SE ZDRAVOTNICKÝM ZAŘÍZENÍM O KLINICKÉM ZKOUŠENÍ PROTOCOL NUMBER: SGS.1656.201XXX PROTOCOL TITLE: A phase II, randomised, double-blind, placebo-controlled clinical trial to assess the safety and...Trial Agreement • January 25th, 2021
This Clinical Trial Agreement (this “Agreement”) is made as of 15 January 2021 (the “Effective Date”) by and between Oblastní nemocnice Kolín a.s., nemocnice Středočeského kraje with a place of business at Žižkova 146, 280 02 Kolín II, and any and all satellite facilities and/or affiliates of the aforementioned (collectively, “Institution”) and Paragon Biomedical Limited, a wholly owned subsidiary of Clinipace, Inc., with a registered address at Third Floor One London Square, Cross Lanes, Guildford, Surrey, GU 1 1UN, United Kingdom and a business address at Aston Court, Kingsmead Business Park, Frederick Place, High Wycombe, Buckinghamshire, HP11 1JU, United Kingdom (together with its affiliates, hereinafter referred to as “CRO”). For purposes of this Agreement, Institution and CRO shall each be defined as a “Party” or collectively as the “Parties”. Tuto Smlouvu o klinickém hodnocení (dále jen „smlouva“) uzavírá k 15.1.2021 (dále jen „datum účinnosti“) společnost Oblastní nemocnice Kol
SOFTWARE/CODE TRIAL AGREEMENTTrial Agreement • October 28th, 2020 • Ontario
This Trial Agreement is between University of Toronto (“UofT”) and ____________________________ (“Customer”) (each a “party”, and collectively the “parties”) and sets forth the provisions under which UofT will provide Customer with certain products listed in Attachment A (“Trial Products”).
CLINICAL TRIAL AGREEMENT SMLOUVA O KLINICKÉ STUDII This Agreement is dated and shall become binding upon the Parties from the date the last Party signs below between: Tato smlouva je datována a vstupuje v platnost dnem, kdy je podepsána poslední...Trial Agreement • April 6th, 2017
ContractTrial Agreement • October 12th, 2016
CLINICAL TRIAL AGREEMENT This CLINICAL TRIAL AGREEMENT (the“Agreement”) is made as of the day the last party to subscribe below (the “Effective Date”), by and between Thomayerova nemocnice, located at Vídeňská 800, Post Code (PSČ): 140 59 Prague 4– Krč, Czech Republic, IČ (company ID number): 00064190, VAT no.: CZ00064190, established by the Ministry of Health and registered under founding charter OP-054-25.11.90, represented by Doc. MUDr. Zdeněk Beneš, CSc., director (the “Institution”), Pharmaceutical Research Associates CZ, s.r.o., located at Praha 7, Jankovcova 1569/2c, Post Code (PSČ): 170 00, Czech Republic, IČ (company ID number): 27636852, the limited liability company duly registered in the Commercial Register of the Czech Republic maintained by the Municipal Court in Prague, Section C, Entry 120574, represented by MUDr. Andrea Klč, Proxy (“PRA”) as clinical research organization acting as an independent contractor for company Teva Branded Pharmaceutical Products R&D, INC, 41
ContractTrial Agreement • April 7th, 2021
This Iberia API and Services Trial Use Agreement (“Trial Agreement”) is entered into by and between:Trial Agreement • February 28th, 2019 • Madrid
CLINICAL TRIAL AGREEMENT SMLOUVA O KLINICKÉ STUDII for Protocol ACE-536-MDS-002 pro Protokol ACE-536-MDS-002 This clinical trial agreement (hereinafter, the “Agreement”) is by and between: Tato Smlouva o klinické studii (dále „Smlouva”), byla uzavřena...Trial Agreement • March 14th, 2022
MUDr. Olga Černá, with DOB XXX, residing at XXX (hereinafter the “Investigator”); MUDr. Olgou Černou, s datem narození XXX, bytem na adrese XXX (dále „Zkoušející”); individually or collectively, as the case may be, referred hereto as the “Party” or “Parties”. jednotlivě nebo případně společně dále „Strana” nebo„Strany”. The Institution and the Investigator are hereinafter called “Institution/Investigator” when it is intended that they be referred to jointly. Zdravotnické zařízení a Zkoušející jsou dále společně označováni jako „Zdravotnické zařízení/Zkoušející”, pokud z kontextu vyplývá, že se odkazuje na oba společně. This Agreement is valid as of the last date of signature below and effective as of the date when it is published in Contracts Register (the “Effective Date”). Tato Smlouva nabývá platnosti ke dni posledního podpisu níže a účinnosti dnem zveřejnění v registru smluv (dále „Datum účinnosti“). WHEREAS VZHLEDEM K TOMU, ŽE (a) The Sponsor conducts business in the development o
Clinical Trial AgreementTrial Agreement • June 12th, 2020 • Nugenerex Immuno-Oncology, Inc. • Pharmaceutical preparations • Pennsylvania
This Clinical Trial Agreement (“Agreement”) is entered into and effective as of the 20th day of November, 2018 (“Effective Date”), by and between NSABP Foundation, Inc., a 501(c)(3) non-profit Pennsylvania membership corporation with its principal office and place of business at Nova Tower 2, Two Allegheny Center, Suite 1200, Pittsburgh, Pennsylvania 15212-5234 (“NSABP”), and Antigen Express, Inc., a Delaware corporation with its principal office and place of business at 33 Redwing Road, Wellesley, MA 02481 (“Antigen Express”). NSABP and Antigen Express shall hereinafter be referred to individually as “Party,” and together as “Parties.”
ContractTrial Agreement • January 8th, 2019
CLINICAL TRIAL AGREEMENT SMLOUVA O PROVEDENÍ KLINICKÉHOHODNOCENÍ STUDY: A Randomised, Multicentre, Investigator-Blind, Parallel-Group Trial to Evaluate the Efficacy and Safety of MC2-01 Cream Compared to Vehicle and Active Comparator in Subjects with Mild-to- Moderate Psoriasis Vulgaris STUDIE: Randomizované, multicentrické, s paralelními skupinami, pro zkoušejícího zaslepené klinické hodnocení k zhodnocení účinnosti a bezpečnosti krému MC2-01 v porovnání s vehikulem a aktivním srovnávacím léčivým přípravkem u pacientů s mírnou až středně závažnou lupénkou PROTOCOL: MC2-01-C7 (incorporated by reference herein) PROTOKOL: MC2-01-C7 (začleněný do této smlouvy tímto odkazem) STUDY PRODUCT: MC2-01 cream HODNOCENÉ LÉČIVO: krém MC2-01 THIS CLINICAL TRIAL AGREEMENT (the“Agreement”) is made and entered into as of the 24th day of October, 2018 between the parties listed below and shall take effect as of the date of publication in the register of contracts (the“Effective Date”), by and among:
ContractTrial Agreement • May 27th, 2021
CLINICAL TRIAL AGREEMENT SMLOUVA O KLINICKÉM HODNOCENÍ Protocol # AP01-005 Protokol číslo AP01-005 This Clinical Trial Agreement (“Agreement”) dated as of the date of last signature and effective as of the date of publication of the Redacted Agreement (hereinafter defined) into the Contracts Registry (hereinafter defined) (“Effective Date”) between Tato smlouva o klinickém hodnocení („smlouva“) ze dne připojení posledního podpisu s účinností k datu uveřejnění upravené smlouvy (definované níže) v registru smluv (definovaném níže) („datum účinnosti“) se uzavírá mezi Syneos Health UK Limited, with principal offices located in the United Kingdom at Farnborough Business Park, 1 Pinehurst Road, Farnborough, Hampshire, GU14 7BF, United Kingdom, including its affiliates, subsidiaries, and specifically its parent company Syneos Health, LLC (“CRO”) společností Syneos Health UK Limited, se sídlem ve Velké Británii na adrese Farnborough Business Park, 1 Pinehurst Road, Farnborough,
ContractTrial Agreement • January 25th, 2022
SMLOUVAO KLINICKÉM HODNOCENÍ CLINICAL TRIAL AGREEMENT Mezi Between společností Seagen Inc., registrovanou ve státě Delaware, se sídlem na adrese 21823 30th Drive SE, Bothell, WA 98021 USA, ménem svým a jménem jejích přidružených společností (dále jen „Zadavatel“) Seagen Inc., a Delaware corporation, with a location at 21823 30th Drive SE, Bothell, WA 98021 USA on behalf of itself and its affiliates (hereinafter referred to as the “Sponsor”) A AND Fakultní nemocnice Královské Vinohrady se sídlem: Šrobárova 1150/50, 100 34 Praha 10, Česká republikaIČ: 00064173 DIČ: CZ00064173státní příspěvková organizace zřízená Ministerstvem zdravotnictví ČRzastoupená: Prof. MUDr. Petrem Arenbergerem, DrSc., MBA, FCMA, ředitelem Číslo jednací: KH 47/2020Nákladové středisko: 52162 Fakultní nemocnice Královské Vinohrady with registered office at: Šrobárova 1150/50, 100 34 Praha 10, Česká republikaID No.: 00064173VAT No.: CZ00064173A state contributory organization established by the Ministry of Health of
TRIAL AGREEMENTTrial Agreement • January 17th, 2020 • Texas
THIS TRIAL AGREEMENT ("AGREEMENT") WILL BECOME A LEGAL AGREEMENT BETWEEN THE USER OF THE DOWNLOADED PRODUCT NAMED IN THE EXPORT VALIDATION SECTION OF THE BMC SUPPORT WEB SITE (WITHIN WWW.BMC.COM) OR ANY SUCCESSOR SITE) OF WHICH THIS AGREEMENT IS A PART ("USER") AND BMC SOFTWARE , INC. OR ITS LOCAL LICENSING AFFILIATE ("BMC"). BY PRESSING THE "I AGREE" BUTTON, YOU REPRESENT AND WARRANT THAT YOU HAVE READ AND UNDERSTOOD THE TERMS OF THIS AGREEMENT, THAT YOU HAVE THE AUTHORITY TO BIND USER TO THIS AGREEMENT, AND THAT USER AGREES TO BE BOUND BY THE TERMS AND CONDITIONS OF THIS AGREEMENT. BMC AGREES TO PERMIT YOU TO DOWNLOAD PRODUCTS ONLY IF AND AFTER YOU AND USER HAVE ACCEPTED ALL OF THESE TERMS BY PRESSING THE "I AGREE" BUTTON.
